Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia by Sharifah Aishah, Wan et al.
  1Ann Rheum Dis Month 2020 Vol 0 No 0
Clinical features of patients with rheumatic 
diseases and COVID-19 infection in 
Sarawak, Malaysia
We read with great interest the article by Ye et al1 describing 
the clinical features and outcomes of patients with rheumatic 
diseases and COVID-19 in Wuhan, China. It concluded that 
length of hospital stay and mortality were similar between 
patients with rheumatic diseases and non- rheumatic groups, 
while respiratory failure was more common in patients with 
rheumatic diseases infected with COVID-19. D’Silva et al2 and 
Zhao et al3 subsequently highlighted the differences of clinical 
severity and outcomes in their respective cohorts of patients with 
rheumatic diseases and COVID-19. Fredi et al4 presented data 
from northern Italy which supported an association of elderly 
age and the presence of comorbidities with a poor outcome of 
COVID-19 infection, rather than the type of rheumatic disease 
or background medications. The Global Rheumatology Alliance5 
has recently published data of characteristics associated with 
hospitalisation for COVID-19 among patients with rheumatic 
diseases. We would like to share the clinical course of COVID-19 
among patients with rheumatic diseases in Sarawak.
We reviewed the medical records of all the patients with rheu-
matic diseases diagnosed with COVID-19. Sarawak recorded 569 
cases of COVID-19 with 17 deaths as of 24 June 2020.6 The confir-
mation of the diagnosis of COVID-19 was based on positive reverse 
transcriptase PCR from the nasopharyngeal swab that detected 
severe acute respiratory syndrome coronavirus 2 from a nasopha-
ryngeal swab specimen. There were four patients with rheumatic 
diseases among the 569 patients with COVID-19 (0.7%). There 
were two systemic lupus erythematosus (SLE), one dermatomyo-
sitis and one scleroderma. Patient 1 had stable SLE treated with 
hydroxychloroquine and sulfasalazine. She also had hypertension 
and obesity and she was a smoker. She was diagnosed with severe 
pneumonia, ventilated and subsequently succumbed to the disease. 
She was diagnosed with COVID-19 posthumously. Patient 2 was 
also a patient with stable SLE on hydroxychloroquine and azathio-
prine, and she developed an SLE flare at admission. Patient 3 was 
80 years old with stable polymyositis on azathioprine. She also had 
diabetes mellitus. Patient 4 was 72 years old with systemic sclerosis 
not on any immunosuppressant. Her comorbidities were lung 
fibrosis, pulmonary arterial hypertension and a caecal malignancy 
which was resected 2 years prior. She recovered from COVID-19 
infection and was discharged home; however, during a follow- up 
call it was discovered that she had died at home. All patients with 
rheumatic diseases had a stable disease prior to COVID-19 infec-
tion, and none of the patients were on glucocorticoids. Table 1 
shows the clinical features of the patients with rheumatic diseases 
and COVID-19 infection.
When we reviewed the data of the 17 COVID-19 deaths from 
Sarawak, there were more men (10 patients) and more patients 
were aged below 65 years (12 patients). The most common comor-
bidities present among the patients who died were hypertension 
(six patients) and diabetes mellitus (five patients). One patient 
had congestive heart failure and one patient had chronic kidney 
disease. There was only one patient with rheumatic disease among 
the 17 COVID-19 mortalities in Sarawak. Although most publi-
cations quoted elderly age as a major risk factor for COVID-19 
mortality, we are unsure of the reason there were more younger 
patients in our COVID-19 mortality cohort.
In conclusion, data from Sarawak showed a low proportion 
of patients with rheumatic diseases among the COVID-19 cases 
mirroring the findings by other authors. These findings seem to 
support that the presence of rheumatic disease does not affect 
the susceptibility of COVID-19 infection or mortality. The risk 
factor for COVID-19 mortality is the presence of comorbidi-
ties. Flare of rheumatic disease is possible during the COVID-19 
infection. As more data are collected, we hope to have a clearer 
picture of rheumatic diseases and COVID-19.
Sharifah Aishah Wan   ,1 Cheng Lay Teh   ,1 
Benjamin Sachdev Manjit Singh,1 Yaw Kiet Cheong,1 Seow Lin Chuah,1 
Ahmad Tirmizi Jobli2
1Rheumatology Unit, Sarawak General Hospital, Kuching, Sarawak, Malaysia
2Universiti Malaysia Sarawak Faculty of Medicine and Health Sciences, Kota 
Samarahan, Sarawak, Malaysia
Correspondence to Dr Sharifah Aishah Wan, Sarawak General Hospital, Kuching, 
Sarawak 93450, Malaysia;  shaishah80@ yahoo. com
Acknowledgements The authors thank the Director- General of Health Malaysia 
for permission to publish this article.
Contributors All authors were in involved in conception or design, or analysis 
and interpretation of data, or both. All authors approved the final version of the 
manuscript.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Correspondence
Table 1 Patients with rheumatic diseases and COVID-19 infection, 
n=4
Clinical features Patients, n (%)
Age >65 2 (50)
Gender
  Female 4 (100)
  Male 0
Rheumatological diagnosis
  Systemic lupus erythematosus 2 (50)
  Polymyositis 1 (25)
  Systemic sclerosis 1 (25)
Comorbidities
  Smoking 1 (25)
  Obesity 1 (25)
  Hypertension 1 (25)
  Diabetes mellitus 1 (25)
  Lung fibrosis and pulmonary arterial hypertension 1 (25)
  Malignancy 1 (25)
Flare of rheumatological disease
  Flare 1 (25)
  No flare 3 (75)
Background rheumatological treatment
  Glucocorticoids 0
  Hydroxychloroquine 2 (50)
  Azathioprine 2 (50)
  Sulfasalazine 1 (25)
Clinical features of COVID-19 infection
  COVID-19 pneumonia 3 (75)
  Supplemental oxygen via nasal cannula 2 (50)
  Ventilation 1 (25)
Treatment of COVID-19
  Steroids 4 (100)
  Hydroxychloroquine 4 (100)
  Lopinavir/ritonavir 3 (75)
Outcome of COVID-19 infection
  Alive 2 (50)
  Death
   Death from COVID-19 1 (25)
   Death from underlying rheumatic disease 1 (25)
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